Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $181.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price target points to a potential upside of 41.72% from the company’s previous close.

A number of other research firms have also weighed in on SRPT. Robert W. Baird lifted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. Citigroup decreased their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Bank of America raised their target price on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Cantor Fitzgerald reduced their target price on Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, Morgan Stanley restated an “overweight” rating and issued a $165.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $187.39.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded up $2.71 during mid-day trading on Thursday, hitting $127.72. The stock had a trading volume of 99,984 shares, compared to its average volume of 1,302,803. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The firm has a market cap of $12.07 billion, a P/E ratio of 1,160.91 and a beta of 0.81. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25. The business has a fifty day moving average price of $138.75 and a 200-day moving average price of $132.67.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.27) earnings per share. On average, equities research analysts expect that Sarepta Therapeutics will post 1.47 EPS for the current year.

Insiders Place Their Bets

In other news, insider Bilal Arif sold 7,859 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. Insiders have sold 52,801 shares of company stock valued at $8,399,586 in the last ninety days. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares in the last quarter. Capital International Investors boosted its stake in Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after acquiring an additional 76,032 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares during the period. Wellington Management Group LLP increased its stake in shares of Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after purchasing an additional 217,810 shares in the last quarter. Finally, Farallon Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.